Drugs / RO5095932
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01017302 | Dec 2009 → Aug 2011 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT00961909 | Jun 2009 → Oct 2010 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO5095932 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01017302 ↗ |
| Route | Subcutaneous | “Patients will be randomized to receive either RO5095932 subcutaneously once weekly or placebo” NCT00961909 ↗ |